Zachary Zubulake

A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain and pricing risks.

Pharma companies could face 100% tariffs under new US rules, with relief available for those prioritizing onshore manufacturing or pricing concessions.

The FDA’s Plausible Mechanism Framework is designed to facilitate the approval of highly individualized therapies for patients with ultra-rare diseases.

The Supreme Court invalidated IEEPA-based tariffs, but pharmaceutical tariffs imposed under Section 232 remain in effect.